Protara Therapeutics Stock Net Asset
| TARA Stock | USD 2.39 0.10 4.37% |
Protara Therapeutics fundamentals help investors to digest information that contributes to Protara Therapeutics' financial success or failures. It also enables traders to predict the movement of Protara Stock. The fundamental analysis module provides a way to measure Protara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protara Therapeutics stock.
Protara | Net Asset |
Protara Therapeutics Company Net Asset Analysis
Protara Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Protara Therapeutics Net Asset | 78.95 M |
Most of Protara Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protara Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Protara Therapeutics is extremely important. It helps to project a fair market value of Protara Stock properly, considering its historical fundamentals such as Net Asset. Since Protara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Protara Total Assets
Total Assets |
|
Based on the recorded statements, Protara Therapeutics has a Net Asset of 78.95 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Protara Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protara Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protara Therapeutics could also be used in its relative valuation, which is a method of valuing Protara Therapeutics by comparing valuation metrics of similar companies.Protara Therapeutics is currently under evaluation in net asset category among its peers.
Protara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Protara Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Protara Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Protara Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Protara Therapeutics' value.| Shares | Ikarian Capital, Llc | 2024-06-30 | 180.7 K | Oppenheimer & Co Inc | 2024-09-30 | 179.1 K | Two Sigma Investments Llc | 2024-06-30 | 155.8 K | Geode Capital Management, Llc | 2024-06-30 | 140.5 K | Blackrock Inc | 2024-06-30 | 115.3 K | Woodline Partners Lp | 2024-06-30 | 100 K | Two Sigma Advisers, Llc | 2024-06-30 | 80.5 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 77.4 K | Lpl Financial Corp | 2024-06-30 | 44 K | Opaleye Management Inc | 2024-06-30 | 2.3 M | Ra Capital Management, Llc | 2024-06-30 | 1.9 M |
Protara Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | (29.52 M) | ||||
| Shares Outstanding | 20.63 M | ||||
| Shares Owned By Insiders | 6.12 % | ||||
| Shares Owned By Institutions | 51.10 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Book | 0.58 X | ||||
| EBITDA | (43.27 M) | ||||
| Net Income | (40.42 M) | ||||
| Cash And Equivalents | 98.46 M | ||||
| Cash Per Share | 8.74 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 28.94 X | ||||
| Book Value Per Share | 6.01 X | ||||
| Cash Flow From Operations | (37.56 M) | ||||
| Short Ratio | 14.46 X | ||||
| Earnings Per Share | (2.64) X | ||||
| Target Price | 29.5 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 49.31 M | ||||
| Total Asset | 78.95 M | ||||
| Retained Earnings | (200.38 M) | ||||
| Working Capital | 62.56 M | ||||
| Net Asset | 78.95 M |
About Protara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out Protara Therapeutics Piotroski F Score and Protara Therapeutics Altman Z Score analysis. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.